Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03322410
Other study ID # PA17003
Secondary ID
Status Not yet recruiting
Phase N/A
First received October 23, 2017
Last updated October 23, 2017
Start date November 1, 2017
Est. completion date November 1, 2020

Study information

Verified date October 2017
Source CHU de Reims
Contact Fatouma TOURE
Phone 0326787638
Email ftoure@chu-reims.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Bioimpedance is recently known to be a reliable, reproducible and validated technic allowing determination of hydratation status in patients with chronic kidney disease treated with peritoneal dialysis (PD). Overhydratation attested by bioimpedance is strongly associated with cardio-vascular morbidity and mortality in patients with PD. Overhydratation might concern more than half of patients at PD initiation, though the underlying mechanism remains unknown.

High peritoneal permeability (HPP) might concern about a third of patients starting a PD, although only a few datas are published on this condition. HPP at initiation of PD is associated with a decrease in both technical and patient survival and might be responsible of ultrafiltration failure. The underlying mechanisms of HPP at initiation of PD also remains unknown.

To our knowledge, the correlation between hydratation status and peritoneal permeability at initiation of peritoneal dialysis remains unknown. Moreover, there is no datas concerning the cinetic evolution of peritoneal permeability; demographic or biologic factors associated with HPP in days and months following PD start.

The aim of the present study is to correlate hydratation status (attested by bioimpedance) and peritoneal permeability at early start of peritoneal dialysis. Thus, we investigated early cinetic of peritoneal permeability at different time point during the first year of peritoneal dialysis and we analyzed the demographical and biological factors associated with HPP and overhydratation during this period.

This study is a prospective, multicentric cohort study. Fourty patients recruited in a two years' period in five centers of nephrology will be included. Hydratation status will be determined with Fluid Overload measurement by bioimpedance technic thanks to BCM system (Fresenius Medical Care®). Peritoneal permeability will be determined by modified Peritoneal Equilibration Test with complete drainage at sixty minutes. Datas will prospectively be collected, including: weight, blood pressure, diuretic posology, diuresis, PD modality, dialysate prescribed.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 40
Est. completion date November 1, 2020
Est. primary completion date November 1, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria:

- End stage chronic kidney disease

- Ambulatory

- Starting a peritoneal dialysis in one of the participant centers

- Accepting the study protocol

- Age > 18yo

Exclusion criteria:

- Age <18yo

- Protected by the law

Study Design


Intervention

Biological:
modified Peritoneal Equilibration test
Peritoneal permeability status determined by modified Peritoneal Equilibration test with complete drainage at 60 minutes as described for Twardowsky " High ": D/P creatinine>0,8; D/D0 glucose<0,25 " High average ": 0,65< D/P creatinine <0,8; 0,25< D/D0 glucose <0,38 " Low average ": 0,5< D/P creatinine <0,65; 0,39< D/D0 glucose < 0,48 " Low " : D/P creatinine<0,5 ; D/D0 glucose>0,49.

Locations

Country Name City State
France Damien JOLLY Reims

Sponsors (1)

Lead Sponsor Collaborator
CHU de Reims

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Hydratation status Fluid overload (FO) measured with BMC bioimpedance system (Fresenius medical care®)
FO < 10th percentile = extracellular dehydration
10th percentile < FO < 90th percentile = extracellular normohydration
FO > 90th percentile = extracellular hyperhydration
Day 7
Secondary Peritoneal permeability Peritoneal permeability status determined by modified Peritoneal Equilibration test with complete drainage at 60 minutes as described for Twardowsky
" High ": D/P creatinine>0,8; D/D0 glucose<0,25
" High average ": 0,65< D/P creatinine <0,8; 0,25< D/D0 glucose <0,38
" Low average ": 0,5< D/P creatinine <0,65; 0,39< D/D0 glucose < 0,48
" Low " : D/P creatinine<0,5 ; D/D0 glucose>0,49.
Day 7
Secondary Hydratation status Fluid overload (FO) measured with BMC bioimpedance system (Fresenius medical care®)
FO < 10th percentile = extracellular dehydration
10th percentile < FO < 90th percentile = extracellular normohydration
FO > 90th percentile = extracellular hyperhydration
Day 45
Secondary Peritoneal permeability Peritoneal permeability status determined by modified Peritoneal Equilibration test with complete drainage at 60 minutes as described for Twardowsky
" High ": D/P creatinine>0,8; D/D0 glucose<0,25
" High average ": 0,65< D/P creatinine <0,8; 0,25< D/D0 glucose <0,38
" Low average ": 0,5< D/P creatinine <0,65; 0,39< D/D0 glucose < 0,48
" Low " : D/P creatinine<0,5 ; D/D0 glucose>0,49.
Day 45
Secondary Hydratation status Fluid overload (FO) measured with BMC bioimpedance system (Fresenius medical care®)
FO < 10th percentile = extracellular dehydration
10th percentile < FO < 90th percentile = extracellular normohydration
FO > 90th percentile = extracellular hyperhydration
Day 365
Secondary Peritoneal permeability Peritoneal permeability status determined by modified Peritoneal Equilibration test with complete drainage at 60 minutes as described for Twardowsky
" High ": D/P creatinine>0,8; D/D0 glucose<0,25
" High average ": 0,65< D/P creatinine <0,8; 0,25< D/D0 glucose <0,38
" Low average ": 0,5< D/P creatinine <0,65; 0,39< D/D0 glucose < 0,48
" Low " : D/P creatinine<0,5 ; D/D0 glucose>0,49.
Day 365
See also
  Status Clinical Trial Phase
Completed NCT05491642 - A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses Phase 1
Recruiting NCT06363097 - Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
Terminated NCT04043026 - The Effects of Renal Function and Atrial Fibrillation on Lipoproteins and Clot Structure/Function
Completed NCT05318014 - Low-protein Formula Supplements in Chronic Kidney Disease N/A
Active, not recruiting NCT06071065 - Clinical Pharmacist Intervention on Medication Adherence and Clinical Outcomes in Chronic Kidney Disease Patients N/A
Completed NCT02878317 - Skin Autofluorescence as a Risk Marker in People Receiving Dialysis.
Not yet recruiting NCT06039254 - Safety and Pharmacokinetics of HRS-1780 in Healthy Subjects and Subjects With Impaired Renal Function Phase 1
Recruiting NCT03160326 - The QUALITY Vets Project: Muscle Quality and Kidney Disease
Withdrawn NCT02885545 - The Strategy to Prevent Hemorrhage Associated With Anticoagulation in Renal Disease Management (STOP HARM) Trial Phase 4
Completed NCT02756520 - Observational Study on CKD Treatment With a Ketosteril Supplemented Protein-restricted Diet (Keto-024-CNI)
Completed NCT02896309 - The Effect of Correction of Metabolic Acidosis in CKD on Intrarenal RAS Activity N/A
Completed NCT02836574 - A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease Phase 2
Completed NCT02888171 - Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency N/A
Completed NCT02875886 - DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease Phase 4
Active, not recruiting NCT02483039 - Nephrologist Follow-up Versus Usual Care After an Acute Kidney Injury Hospitalization N/A
Completed NCT02369549 - Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease Phase 3
Completed NCT02992548 - Effect of Pravastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease Phase 4
Terminated NCT02543177 - Optimised Procedure in Patients With NSTEMI and CKD N/A
Recruiting NCT02205944 - Impact of Presurgical Exercise on Hemodialysis Fistula Outcomes N/A
Active, not recruiting NCT02231138 - Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease Phase 4